Roche: FDA approves allergy treatment

(CercleFinance.com) - Roche announces that the FDA has approved Xolair as the first and only drug for children and adults with one or more food allergies.


The approval is based on data from the NIH-sponsored phase III OUTMATCH study, which showed that a significantly higher proportion of food-allergic patients, as young as one year of age, treated with Xolair could tolerate small amounts of peanut, milk, egg and cashew without allergic reaction. compared with placebo.

Over 40% of children and more than half of adults with food allergies experienced a severe reaction at least once.

Detailed OUTMATCH results will be presented at a late-breaking symposium at the AAAI 2024 Annual Meeting.

Xolair offers patients and their families an important new treatment option that can help redefine the way food allergies are managed and reduce the often severe allergic reactions that can result from exposure to food allergens, Roche said.


Copyright (c) 2024 CercleFinance.com. All rights reserved.